149517-92-0

Basic information

• Product Name: BENZOIC ACID, 4-BROMO-3,5-DIETHOXY-, ETHYL ESTER
• Synonyms: BENZOIC ACID, 4-BROMO-3,5-DIETHOXY-, ETHYL ESTER;ethyl 4-broMo-3,5-diethoxybenzoate
• CAS NO: 149517-92-0
• Molecular Formula: C₁₃H₁₇BrO₄
• Molecular Weight: 317.177
• Mol File: 149517-92-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 390.038 °C at 760 mmHg
• Flash Point: 189.689 °C
• Appearance: /
• Density: 1.316 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: BENZOIC ACID, 4-BROMO-3,5-DIETHOXY-, ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIC ACID, 4-BROMO-3,5-DIETHOXY-, ETHYL ESTER(149517-92-0)
• EPA Substance Registry System: BENZOIC ACID, 4-BROMO-3,5-DIETHOXY-, ETHYL ESTER(149517-92-0)

Safety Data

• Hazardous Substances Data: 149517-92-0(Hazardous Substances Data)

Usage

General Description

BENZOIC ACID, 4-BROMO-3,5-DIETHOXY-, ETHYL ESTER is a chemical compound with the molecular formula C12H16BrO4. It is an ethyl ester derivative of 4-bromo-3,5-diethoxybenzoic acid. BENZOIC ACID, 4-BROMO-3,5-DIETHOXY-, ETHYL ESTER is commonly used in the synthesis of pharmaceuticals and other organic compounds. It possesses both bromo and diethoxy functional groups, making it useful in the development of new applications in drug research and development. It is also considered a potential candidate for the development of new chemical entities with therapeutic properties.

Upstream product

• 64-67-5 diethyl sulfate 
• 16534-12-6 3,5-dihydroxy-4-bromobenzoic acid 
• 75-03-6 ethyl iodide 

Downstream Products

• 149517-94-2 methyl 4-bromo-5-ethoxy-3-hydroxybenzoate 
• 149517-95-3 methyl 4-bromo-5-ethoxy-3-hydroxy-2-nitrobenzoate 
• 149517-96-4 4-bromo-5-ethoxy-3-hydroxy-2-nitrobenzoic acid 
• 1254732-07-4 methyl 4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoate trifluoroacetic acid 
• 1254733-98-6 4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid trifluoroacetic acid 

Relevant articles and documents

SSTR5 ANTAGONISTS

This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus

Somatostatin receptor subtype 5 (SSTR5) has emerged as a novel attractive drug target for type 2 diabetes mellitus. Starting from N-benzyl azetidine derivatives 1 and 2 as in-house hit compounds, we explored the introduction of a carboxyl group into the t

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.